Physician profile
Monisha Singh
NPI 1073655965
$1,745.45
in general payments reported to CMS, 2019-2025
16 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $13.97 · 2022: $18.00 · 2023: $1,119 · 2024: $101 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $694 · Food and Beverage: $631 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $694.08 |
| Food and Beverage | $630.75 |
| Education | $259.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $827.51 | 2023 | Xpovio |
| Pfizer INC. | $154.56 | 2019-2023 | |
| Pharmaessentia USA Corporation | $124.98 | 2025 | Besremi |
| Iovance Biotherapeutics, INC. | $124.53 | 2024-2025 | Amtagvi |
| Regeneron Healthcare Solutions, INC. | $123.70 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $100.96 | 2024-2025 | |
| Aadi Bioscience, INC. | $99.00 | 2023 | Fyarro |
| Seagen INC. | $96.00 | 2025 | |
| Abbvie INC. | $23.15 | 2023 | Avycaz |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
| Gilead Sciences, INC. | $18.00 | 2022 | |
| Eisai INC. | $13.97 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monisha Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.